Edwards Lifesciences Corp (EW) has been making significant strides in the market. Following an analyst upgrade, the company's shares reached a new 12-month high. BTIG has maintained its buy recommendation on EW, while Stifel and Royal Bank of Canada have raised their price targets to $100. In addition, EW is targeting an EPS of $2.80-$2.95 by 2026, with TMTT up 35%-45%. Some significant investment movements include Schroder selling 13,594 shares, while Amundi, Epoch Investment Partners, First National Advisers, and Korea Investment CORP boosted their stock positions. Ahead for Edwards Lifesciences is robust TAVR growth, which is projected to drive the company's Q3 earnings. The company has also reiterated its 2025 guidance and issued a 2026 forecast. Looking back, an investment of $1,000 in Edwards Lifesciences 20 years ago would have yielded remarkable returns. Lastly, Edwards Lifesciences is gradually winning the confidence of investors as demonstrated by incoming share purchases. In summary, the company's strong valuation and consistent performance is attracting notable interest.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 06 Dec 2025 16:28:47 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 3
